Serum Institute gets approval to resume Indian trial of AstraZeneca COVID vaccine: source
By Editor - Wed Sep 16, 1:16 am
Serum Institute of India has received Indian regulatory approval to resume local clinical trials of AstraZeneca’s potential COVID-19 vaccine, a source familiar with the matter said on Wednesday. The approval came from the Drugs Controller General of India, the source said. AstraZeneca has resumed British clinical trials of the vaccine – one of the most advanced in development for COVID-19 – after they were paused earlier this month following a serious side effect in a trial participant.